<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28574">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02110316</url>
  </required_header>
  <id_info>
    <org_study_id>47955</org_study_id>
    <nct_id>NCT02110316</nct_id>
  </id_info>
  <brief_title>Bioavailability of Voriconazole</brief_title>
  <official_title>Bioavailability of Voriconazole in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to obtain the absolute bioavailability of voriconazole in
      critically ill ICU patients, because pharmacokinetics can be different in critically ill
      patients due to alterations in function of various organs and body systems compared with
      healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bioavailability of voriconazole, based on healthy volunteers, is estimated to be &gt;90%.
      Due to the high bioavailability of voriconazole, switching between oral and intravenous
      administration is permitted if clinically allowed. Few data are available for the
      bioavailability of voriconazole in critically ill patients. However, to obtain a therapeutic
      concentration of voriconazole (&gt;1.5 mg/L, which is associated with a beneficial response to
      treatment) one study showed that a higher oral dose is required compared with the
      intravenous dose, to obtain this therapeutic concentration. Therefore, the pharmacokinetics
      can be changed in critically ill patients, including bioavailability.

      In this study, patients who receive voriconazole orally (prescribed by their attending
      physician) will receive one intravenous dose of voriconazole instead of the oral dose. The
      intravenous dose will be the same as the oral dose voriconazole.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>The bioavailability of voriconazole in critically ill patients</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bioavailability will be determined by comparing the area under the concentration time curve (AUC) of an intravenous and oral dose of voriconazole.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of bioavailability of voriconazole with disease severity</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease severity will be determined using the APACHE IV score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of bioavailability of voriconazole with the degree of inflammation</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the degree of inflammation C-reactive protein (CRP) will be determined</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Voriconazole</condition>
  <condition>Bioavailability</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Bioavailability</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 arm, different dosage form</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosage form of voriconazole</intervention_name>
    <description>Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).</description>
    <arm_group_label>Bioavailability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged â‰¥ 18 yrs;

          -  Treatment with voriconazole;

          -  Admission to an ICU;

          -  Written informed consent.

        Exclusion Criteria:

          -  Blood sampling by central venous catheter or peripheral cannula not possible;

          -  Concomitantly using a strong inhibitor or inducer of cytochrome P450.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <phone>+31503614070</phone>
    <email>j.w.c.alffenaar@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
      <phone>+31503614070</phone>
      <email>j.w.c.alffenaar@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 12, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
